Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: A randomized multicenter trial

Steven P. Schulman, Pascal J. Goldschmidt-Clermont, Eric J. Topol, Robert M. Califf, Frank I. Navetta, James T. Willerson, Nisha C. Chandra, Alan D. Guerci, James J. Ferguson, Roben A. Harrington, A. Michael Lincoff, Steven J. Yakubov, Paul F. Bray, Raymond D. Bahr, Christopher L. Wolfe, Paul G. Yock, H. Vernon Anderson, Thomas W. Nygaard, Steven J. Mason, Mark B. EffronAnil Fatterpacker, Stephen Raskin, Jack Smith, Lori Brashears, Patricia Gottdiener, Charles Du Mee, Michael M. Kitt, Gary Gerstenblith

Research output: Contribution to journalArticle

Abstract

Background: Although aspirin is beneficial in patients with unstable angina, it is a relatively weak inhibitor of platelet aggregation. The effect of Integrelin, which inhibits the platelet fibrinogen receptor glycoprotein (GP) IIb/IIIa, on the frequency and duration of Holter ischemia was evaluated in 227 patients with unstable angina. Methods and Results: Patients received intravenous heparin and standard anti-ischemic therapy and were randomized to receive oral aspirin and placebo Integrelin; placebo aspirin and low-dose Integrelin, 45 μg/kg bolus followed by a 0.5-μg · kg -1 · min -1 continuous infusion; or placebo aspirin and high-dose Integrelin, 90 μg/kg bolus followed by a 1.0-μg · kg -1 · min -1 constant infusion. Study drug was continued for 24 to 72 hours, and Holter monitoring was performed. Patients randomized to high-dose Integrelin experienced 0.24±0.11 ischemic episodes (mean±SEM) on Holter lasting 8.41±5.29 minutes over 24 hours of study drug infusion. Patients randomized to aspirin experienced a greater number (1.0±0.33, P

Original languageEnglish (US)
Pages (from-to)2083-2089
Number of pages7
JournalCirculation
Volume94
Issue number9
Publication statusPublished - 1996

    Fingerprint

Keywords

  • angina
  • integrins
  • ischemia
  • platelets

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Schulman, S. P., Goldschmidt-Clermont, P. J., Topol, E. J., Califf, R. M., Navetta, F. I., Willerson, J. T., ... Gerstenblith, G. (1996). Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: A randomized multicenter trial. Circulation, 94(9), 2083-2089.